Corporate

Corporate Law360 provides breaking news and analysis of legal and regulatory issues affecting companies and their counsel. Coverage includes emerging regulation, legislation, and litigation that broadly impacts corporations.



Sign up for a 7-day FREE trial today!



Latest News in Corporate

  • September 11, 2026

    Taxation With Representation: Paul Weiss, Troutman, Wachtell

    In this week's Taxation With Representation, GE Aerospace buys Consolidated Precision Products from private investment firms Warburg Pincus and Berkshire Partners, Independence Realty Trust Inc. and Centerspace agree to merge, and EverBank Financial Corp. and WaFd Inc. agree to combine through a reverse merger.

  • September 11, 2026

    Compliance Lessons From Agriculture Co. Mexican Bribe DPA

    Agricultural company Scoular’s recently announced deferred prosecution agreement over alleged Foreign Corrupt Practices Act violations at the U.S.-Mexico border reinforces the U.S. Department of Justice’s focus on cartels, and companies must accordingly ensure they address risks associated with the use of customs brokers, says Adam Safwat at Foley Hoag.

  • September 10, 2026

    Huawei Ripped Off Amazon Cloud Platform IP, Jury Hears

    A former engineer for a U.S. subsidiary of Huawei on Thursday testified that she was shocked and upset after a colleague boasted of co-opting patented code used in Amazon's cloud computing platform, the first of several Huawei employees that are expected to take the stand in the Chinese telecommunications company's RICO trial in New York federal court. 

  • September 10, 2026

    Thomson Reuters Says DOJ AI Stance Doesn't Back Ross

    Thomson Reuters told the Third Circuit Thursday in defunct legal tech startup Ross Intelligence's interlocutory appeal of a summary judgment ruling that it infringed Westlaw headnotes that a statement by the U.S. Department of Justice flagged by Ross does not support its fair-use defense.

  • September 10, 2026

    Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told

    Nektar Therapeutics' damages expert told a California federal jury on Thursday that Eli Lilly & Co. could owe the biotechnology company nearly $1 billion if it finds that the pharmaceutical giant breached a license agreement to co-develop Nektar's autoimmune-disease drug Rezpeg.

See more Corporate news

Corporate

Areas of Coverage

  • CORPORATE GOVERNANCE
  • Company bylaws
  • Fiduciary duties of executives
  • Executive compensation
  • Insider dealings and corporate disclosure
  • Ethical and professional guidelines
  • Shareholder and employee rights
  • ENFORCEMENT
  • Corporate formation rules
  • Securities issuances
  • Employment rules and regulations
  • Product safety issues, including labeling of products and required safety warnings
  • LITIGATION
  • Major litigation in intellectual property, antitrust, securities, and employment law
  • Privacy and data security issues
  • Product safety and marketing disputes
  • Merger-related suits, including disputes over contracts, break-up fees, and poison pills
  • Insurance issues, including coverage for general liability and directors’ and officers’ liability
  • Debtor and creditor disputes in bankruptcies
  • PROFILES
  • Personnel moves
  • Profiles of corporate practices
  • Corporate legal department trends

Readership

  • Outside counsel with a broad legal practice
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Chief legal officers and chief risk management officers at Fortune 1000 companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals